Cosmetic delivery system for salicylic acid and process for preparation of same

Abstract: A cosmetic composition which includes: a) membrane lipids dispersed in the form of liposomes; b) un-neutralized salicylic acid localized within the membrane lipid bilayer of the liposome; c) other cosmetic ingredients located in either the membrane compartment, or in either of the external or internal aqueous compartments or some combination thereof; d) an organic, water-soluble membrane-impermeant base; and, e) water. This composition enables the inclusion of salicylic acid as the free acid in products of neutral pH.

Description: The present invention relates to liposomal dispersions containing un-neutralized salicylic acid and a process for their preparation. More particularly, the present invention relates to a cosmetic dispersion that allows for the incorporation of large amounts of salicylic acid within the hydrophobic compartment of the liposomal bilayer, without the necessity of pre-neutralization or salt formation of the corresponding salicylate, while simultaneously permitting the pH of the external aqueous compartment to be adjusted with soluble organic bases. Salicylic acid is an active ingredient long-known to those skilled in the formulation of cosmetic and topical products. Dandruff has been treated with ointments containing 2 percent salicylic acid. As a keratolytic agent, salicylic acid will soften and swell the epidermis. At concentrations higher than 2 percent, salicylic acid is an efficacious anti-acne agent and is bactericidal. The formation of salts of salicylic acid, such as sodium salicylate formed by the combination of salicylic acid and sodium hydroxide, greatly improves the water solubility of the free acid, but substantially modifies the biological response to salicylic acid. Salicylic acid is nearly insoluble in water (limit of solubility approximately 0.2 percent at room temperature). When incorporated into cosmetic solutions, salicylic acid requires the addition of cosolvents such as ethanol, isopropanol or dimethylsulfoxide. These solutions exhibit low pH (approximately 2), and as a consequence may be irritating to the skin. Development of aesthetic cosmetic formulations under these constraints of pH greatly limits the range of formulation types. For example, hydrocolloid gels will not form at this extreme of pH. Many other cosmetic ingredients are rendered unstable under these conditions. A general reference for the formulation of cosmetic compositions containing salicylic acid follows: Wilkinson, J.B. and Moore, R.J. Harry's Cosmeticology (Seventh Edition) , 1982, Chemical Publishing Co., Inc., New York, New York, pp. 19, 45, 122, 687, 366. A general refernce for the application of liposomes to cosmetics follows: Hayward, J.A. and Smith, W.P. Potential Applications of Liposomes in Cosmetic Science , in Cosmetic and Toiletries , 105 : 47 - 54, 1990. The Won U.S. Patent No. 5,145,675 is related to a topical delivery system for active ingredients such as salicylic acid, whereby controlled release is achieved by the gradual desorption of the active ingredient from solid, porous particles. The Cioca et al . U.S Patent No. 4,999,348 is related to cosmetic and pharmaceutical compositions containing liquid crystals and liposomes, and methods of incorporating such ingredients into cosmetic formulations. The Desai et al . U.S. Patent No 4,816,247 is related to emulsions of ionizable hydrophobic drugs including hydroxybenzoic acid (salicylic acid). The Popescu et al . U.S. Patent 4,708,861 is related to liposome gel compositions. Th e Allen U.S. Patent No. 4,895,727 relates to topical treatment methods which utilize water-soluble zinc compound to enhance the reservoir effect of active ingredients in the skin, including salicylic acid. The Story and Flynn U.S. Patent No. 4,944,949 relates to micellar dispersions of non-steroidal anti-inflammatory drugs (NSAID's), such as salicylic acid, with surfactants such as polyethoxylated nonionics. The Shroot et al. U.S. patent No. 5,151,534 relates to eicosenoid lipids and their application in pharmacy and cosmetics. These lipids may be formulated with salicylic acid and may be incorporated into liposomes. The Tzeghai and Leis U.S. Patent No. 4,755,387 relates to oral therapeutics, such as salicylic acid, which have a coating of lipids to provide release of the therapeutic in the intestines. The lipid coatings are non-liposomal, and are comprised of neutral lipids and esters. The DuBois U.S. Patent No. 5,075,113 relates to phospholipid-based emulsions of paraffins which may contain salicylic acid. The Gajdos and Metzen U.S. Patent No. 5,114,928 relates to solid dosage forms comprised of non-liposomal phospholipid and utilizes salicylic acid as a stabilizer. The Dunphy et al . U.S. Patent No. 5,085,856 relates to a formulation for a water-in-oil emulsion comprising phospholipids which may include liposomes, and, within the emulsion, salicylic acid. The Weiner and Fielder U.S. Patent No. 5,049,392 relates to a method of producing liposomes specifically via osmotic shock; the resultant liposomes may contain NSAID's including salicylic acid. The Fountain U.S Patent No. 5,133,965 relates to a wound dressing comprised of liposomes generated by a solvent-dilution method; the resultant liposomes may contain salicylic acid. It is therefore an object of the present invention to provide a liposomal composition, particularly a topical formulation, and a process for its preparation, that permits the generation of liposomes containing salicylic acid, that allows the adjustment of the pH of the external aqueous compartment to pH ranges approaching neutrality, and that ensures that the greater proportion of the salicylic acid in the formulation remains as the free acid. At this point it may be noted that United States Patent No. 4,217,344 discloses aqueous dispersions of lipid spheres which are said to encapsulate a high concentration of active substances - but this of course refers to hydrophilic substances in the encapsulated aqueous phase within the lipid spheres - quite unlike the liposomes of the present invention which, as appears below, contain liphophilic un-neutralized salicylic acid within the liphophilic environment inside the lipidic bilayers themselves. And for completeness it may also be noted that United States Patent No. 4,981,681 discloses a lotion mixture, for psoriasis, which contains lecithin, an organic base and salicylic acid - but, quite unlike the present invention, there is no formation of any liposome, and thus no separation by the liposomal bilayers of the organic base from the salicylic acid. These therefore would neutralize each other, rendering the salicylic acid largely incapable of performing its intended function. According to the present invention there is provided a cosmetic composition containing: a) an effective amount of membrane-forming lipids which form liposomal bilayers, said lipids forming liposomes with liposomal bilayers which include an hydrophobic environment; b) an effective amount of salicylic acid which is localized within said environment; c) an effective amount of a water-soluble organic base unable to permeate into the liposomal lipidic bilayers; d) optionally other suitable cosmetic ingredients; and e) the balance, up to 100 percent by weight of the total composition, being water. As indicated above, the composition may optionally contain an effective amount of any other suitable cosmetic or pharmaceutical ingredient(s), among which and specifically suited to the purpose are any of the many commercially-available raw materials intended to function as antioxidants, preservatives, anti-inflammatory agents and hydrocolloids. The cosmetic liposomes of the invention can optionally also comprise other ingredients as are conventionally employed in cosmetic products. Examples of other ingredients include, but are not limited to, perfumes, colorants such as staining dyes and pigments, humectants, anti-dandruff agents, anti-acne agents, germicides, sunscreens, emollients, vitamins, sterols and other lipids. Particularly preferred pigments, when present, include calcium oxide, barium oxide and aluminum oxide, iron oxides, titanium dioxide, and mica. Particularly preferred humectants include butylene glycol, glycerol, sorbitol and other polyols. Particularly preferred antidandruff agents include selenium, selenium salts, resorcinol and coal tar. Particularly preferred anti-acne agents include benzoyl peroxide and resourcinol. Particularly preferred germicides include the parabens, kathon CG, phenoxyethanol and germall 115. Particularly preferred sunscreens include octyl methoxycinnimate and butyl methoxydibenzoylmethane. Particularly preferred emollients include cyclomethicone, dimethicone, and lanolin derivatives. Particularly preferred hydrocolloids include hyaluronic acid, guar, carrageenan, alginic acid, polymethacrylates and their derivatives. Particularly preferred vitamins include vitamin E, vitamin A palmitate and Vitamin C. Particularly preferred sterols include sitosterol, stigmasterol, phytosterols and cholesterol. Particularly preferred other lipids include ceramides, cerebroside and other sphingolipids The preferred method of manufacture involves extrusion under conditions of extremely high pressure generated by commercially available equipment such as the Microfluidizer (Microfluidics Corp., Newton, Mass.). The liposomes are produced in the presence of insoluble salicylic acid and the bilayer-forming lipids devoid of any organic bases or buffers. After production, the pH of the external aqueous compartment is adjusted with a membrane-impermeant organic base. According to another aspect of the invention there is also provided a process for the preparation of a cosmetic composition as claimed in any of the preceding claims, which includes the steps of: a) dispersing by mixing the membrane-forming lipids, and any soluble component intended to be encapsulated within the internal aqueous compartment of the liposome, in the aqueous phase of the composition; b) adding the salicylic acid to the crude dispersion without neutralization; c) adding any other lipid-soluble components; d) processing the crude, hydrated dispersion under conditions of high-shear adequate to manufacture liposomes; e) adding any other components intended to be localized in the aqueous compartment outside the liposome; and f) neutralizing the aqueous phase external said liposomes by the addition of said organic base. the process is either one or two staged. In the two-stage process the first stage is the formation of a liposome composition pre-product and the second stage is the preparation of the final product by combining the pre-product with a mixture of the other components. If the process is carried out by means of a one-stage process then the final product is directly produced without the formation of a pre-product. Particularly preferred membrane lipids include the synthetic phospholipids such as dipalimitoylphosphatidylcholine, natural phospholipids such as soya lecithin or egg yolk lecithin, phosphatidylethanolamines, phosphatidylserines, cereamides, cerebrosides, and phosphatidylglycerides. Particularly preferred organic bases include the basic amino acids such as arginine, lysine and glutamine, and triethanolamine. An effective amount of the membrane-forming lipid phase is preferably form 0.1% to 10% by weight, more preferably from 0.5% to 5.0% by weight, and most preferably form 1.0% to 4.0% by weight, based upon the total composition weight. An effective amount of salicylic acid is from 0.05% to 20% by weight, more preferably from 1% to 15% by weight, and moist preferably 5% to 12% by weight, based upon the total composition weight. An effective amount of organic base is from 0.05% to 25% by weight, more preferably form 1% to 20% by weight, and most preferably form 2% to 15% by weight, based upon the total composition weight. The cosmetic composition of the invention is useful as a moisturiser, a moisturising gel, an anti-dandruff lotion, a cleanser and a toner. The present invention will now be described in greater detail with reference being made to the drawing and the following examples and preferred embodiments. FIG. 1 represents a penetration study for salicylic acid recovered from skin strips of human panalists following application of liposomes containing salicylic acid. In a preferred embodiment, the cosmetic composition of the present invention comprises: a) 0.1% to 10% by weight of a membrane-forming lipid phase; b) 0.05% to 20% by weight of salicylic acid; c) 0.05% to 25% by weight of arginine or a similar water-soluble organic base; d) 40% to 99.8% by weight of water; e) 0% to 20% by weight of other suitable cosmetic ingredients, and with all weight percentages based upon the total % composition weight. The advantages of the present invention include the fact that the cosmetic composition has the unexpected ability to sustain a neutral pH (7.0) in the external aqueous milieu, without neutralizing the salicylic acid to the corresponding salicylate. Once neutralized, the bulk dispersion can be utilized in a wide array of finished product types. In a more preferred embodiment, the cosmetic composition of the present invention comprises: a) 0.5% to 5% by weight of a membrane-forming lipid phase; b) 1.0% to 15% by weight of salicylic acid; c) 1.0% to 20% by weight of arginine or a similar water-soluble organic base; d) 50% to 98.5% by weight of water; e) 1% to 20% by weight of other suitable cosmetic ingredients, and with all weight percentages based upon the total % composition weight. In a most preferred embodiment, the cosmetic composition of this invention comprises: a) 1% to 4% by weight of a membrane-forming lipid phase; b) 5% to 12% by weight of salicylic acid; c) 2% to 15% by weight of arginine or a similar water-soluble organic base; d) 60% to 90% by weight of water; e) 5% to 15% by weight of other suitable cosmetic ingredients, and with all weight percentages based upon the total % composition weight. The ingredients used in the composition of this invention should be of a quality or purity (such as U.S.P. or N.F.) suitable for cosmetic use and should be compatible when used together in a particular composition. Unless indicated otherwise, the physical properties of the components of the composition of the present invention specified herein are the properties of these components before they are mixed with the composition's other ingredients. Among the commercially available suitable membrane forming lipids are the various purified soya lecithins available from Natterman (Cologne, Germany), Lucas Meyer (Illinois), Avanti Polar Lipids (North Dakota), and Nikko Chemical (Tokyo, Japan). Among the commercially suitable soluble organic bases are L-Arginine, L-Lysine, L-Glutamine, available from Tanabi (Woodcliff lake, New Jersey) and Triethanolamine, available from Acro Chemical Company (Farmingdale, New York). Salicylic acid is available from Universal Preserv-A-Chem, Inc. (Brooklyn, New York). The composition of the present invention may be prepared by the following process steps, which are carried out at room temperature (25°C) under 1 atmosphere pressure of argon gas (to limit any opportunity for oxidation): a) Use of a marine or propellar-type mixer to disperse the membrane-forming lipid in the total quantity of water available to the formulation. In this first embodiment, the mixing occurred at 500 to 1500 rpm and lasted for 1 hour. The remaining water-insoluble phases are then added to the wetted lipids, along with the salicylic acid and any germicides or preservatives. Any additional cosmetic excipients or active ingredients are then added to the batch. In this second embodiment, the mixing was continued at 500 to 1500 rpm for 1 hour with caution to avoid vortex and entrainment of air. b) In order to facilitate hydration of the batch prior to high-shear processing, the batch was then homogenized with a rotot/stator-type homogenizer running at 3,000 rpm for 30 minutes. c) At this stage the batch was subjected to high-shear processing, specifically microfluidization. In this process, the liquid is extruded through two 100 micron pores. The jetting streams collide within an interaction chamber, and then the liquid is extruded to ambient pressure. The combination of shear and prssure change completes the dispersion of the insoluble phases and produces liposomes as verified by freeze-fracture electron microscopy. d) The pH of the batch at this stage is acidic (pH approximately 2.0) due to the limited solubility of salicylic acid in water (approximately 0.2%). A batch titration was then performed with arginine to acheive a final pH of 6.5 to 7.5. the amount of arginine required is determined by the total availability of titratable groups. However, less than 1% salicylic acid is neutralized by this process. e) Finally, any necessary additional cosmetic ingredients meant to occupy solution volumes outside the liposomes may be added. Such materials might include thickeners or other rheologic agents, emollients, humectants and germicides. The above procedure is generic to all of the specific types of compositions. EXAMPLES Example 1 (Salicylic Acid Liposome) Phase Ingredient Parts by Weight 1 Lecithin 1.0 1 Water 83.0 2 Salicylic Acid 10.0 2 Phenonip 1.0 2 Vitamin E Acetate 1.0 3 Arginine 4.0 The ingredients in Phase 1 were mixed by a propeller rotating at 500 to 1,500 rpm for one hour. The ingredients of Phase 2 were added, and mixing continued for an additional one hour. The batch was then subjected to high-shear extrusion at 12,000 psi of pressure through a 100 micron pore. Dynamic laser light scattering revealed a particle diameter of 200 nanometers. Carboxyfluoroscein labeling indicated intact liposomes. Freeze-fracture transmission electron microscopy substantiated the presence of vesicles. After microfluidization, the arginine was added, and the pH increased from 2.0 to 6.7. FIG. 1 contrasts the penetration of salicylic acid into the epidermis of the volar forearm of human panelists. The degree of penetration was determined by HPLC analysis of solubilized Scotch Tape strips. A control comprised of a sodium sterate emulsion containing 10 percent salicylic acid was prepared. Both the experimental liposome and the control emulsion were diluted 1 to 10 in a gel of polymethacrylate and applied at equivalent sites. The "Figure" reveals that the penetration of salicylic acid was facilitated by liposomal inclusion. The level of liposomal salicylic acid was found to be, and continued to be, safe, non-irritating, moisturizing product. Example 2 (Moisturizing Liposome) Phase Ingredient Parts by Weight 1 Lecithin 2.0 1 Sitosterol 0.5 1 Water 84.5 1 Trehalose 1.0 1 NaPCA 1.0 2 Salicylic Acid 5.0 2 Phenonip 1.0 2 Vitamin E Linoleate 1.0 2 Vitamin A Palmitate 1.0 3 Arginine 3.0 The product was processed utilizing a procedure analogous to that described above for Example 1. The sample was diluted 1 to 4 in a 0.5 percent polymethacrylate gel and applied to the skin. After two hours, the final product was found to be, and continued to be, safe, non-irritating, moisturizing product. Example 3 (Anti-Acne Liposome) Phase Ingredient Parts by Weight 1 Lecithin 2.0 1 Cholesterol 0.3 1 Glycine 1.0 1 Resorcinol 0.1 1 Water 86.6 2 Salicylic Acid 5.0 2 Chlorphenesin 2.5 3 Arginine 2.5 The product was processed utilizing a procedure analogous to that described above for Example 1. The sample was diluted 1 to 4 in a 0.5 percent polymethacrylate gel. After dilution, the product was innoculated with 1 x 10 7 cfu per gram of p.acne . At 48 hours, no bacteria could be detected. The final product was applied to the skin beneath the eye of an adult human male. After two hours, no indication of irritation was present, and the product continued to be a safe and non-irritating anti-acne formulation. Example 4 (Moisturing Liposome Gel) Phase Ingredient Parts by Weight (a) Preproduct 1 Lecithin 2.0 1 NaPCA 1.0 1 Glycine 1.0 1 Trehalose 1.0 1 Water 86.6 2 Salicylic Acid 2.0 2 Chlorphenesin 2.5 3 Arginine 0.5 (b) Final Product 4 Butylene glycol 3.1 4 Carbomer 941 0.3 The product was processed utilizing a procedure analogous to that described above for Example 1. The sample was found to have a viscosity of 28,000 mPa.s (centipoise). The final product was topically applied to the skin of the forearm of adult human male. After two hours, no indication of irritation was present, and the product continued to be a safe and non-irritating moisturizer. Thus, while the aforementioned embodiments of the present invention have been shown and described, it will be obvious that many changes and modifications may be made thereunto without departing from the spirit and scope of the invention as defined in the appended claims.

Claims: A cosmetic composition comprising: a) an effective amount of membrane-forming lipids which form liposomal bilayers, said lipids forming liposomes with liposomal bilayers which include an hydrophobic environment; b) an effective amount of salicylic acid which is localized within said hydrophobic environment ; c) an effective amount of a water-soluble organic base unable to permeate into the liposomal lipidic bilayers; d) optionally other suitable cosmetic ingredients; and e) the balance, up to 100% by weight of the total composition, being water. A cosmetic composition as claimed in claim 1, which comprises: a) from 0.1% to 10% by weight of the membrane-forming lipids; b) from 0.05% to 20% by weight of salicylic acid; c) from 0.05% to 25% by weight of the water-soluble organic base; d) from 0% to 20% by weight of other suitable cosmetic ingredients; and e) from 40% to 99.8% by weight of water; all weight percentages being based upon the total weight of the composition. A cosmetic composition as claimed in claim 1, which comprises: a) from 1% to 4% by weight of the membrane-forming lipids; b) from 5% to 12% by weight of salicylic acid; c) from 2% to 15% by weight of the water-soluble organic base; d) from 5% to 15% by weight of other suitable cosmetic ingredients; and e) from 60% to 90% by weight of water. A process for the preparation of a cosmetic composition as claimed in any of the preceding claims, which includes the steps of: a) dispersing by mixing the membrane-forming lipids, and any soluble component intended to be encapsulated within the internal aqueous compartment of the liposome, in the aqueous phase of the composition; b) adding the salicylic acid to the crude dispersion without neutralization; c) adding any other lipid-soluble components; d) processing the crude, hydrated dispersion under conditions of high-shear adequate to manufacture liposomes; e) adding any other components intended to be localized in the aqueous compartment outside the liposome; and f) neutralizing the aqueous phase external said liposomes by the addition of said organic base. A process as claimed in claim 4, in which one first prepares a pre-product and subsequently produces the final product therefrom. A process as claimed in claim 4, in which one directly produces the final product without the preparation of a pre-product.

Inventors: BROWN MIRIAM, CECCOLI JOSEPH DOMINIC, GOLDSTEIN MINDY SUE, HAYWARD JAMES ARTHUR, BROWN, MIRIAM, CECCOLI, JOSEPH DOMINIC, GOLDSTEIN, MINDY SUE, HAYWARD, JAMES ARTHUR
Applicants: COLLABORATIVE LAB INC, COLLABORATIVE LABORATORIES INC.
Application year: 1993
Main classification: A61K7
IPC codes: B01J13, A61K9, A61K8, A61Q19, A61K31, A61P17